The role of gastric mucins and mucin-related glycans in gastric cancers.
Helicobacter pylori
gastric cancer
gastric mucin
glycans
intestinal metaplasia
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
19 Jul 2024
19 Jul 2024
Historique:
revised:
22
06
2024
received:
23
04
2024
accepted:
02
07
2024
medline:
20
7
2024
pubmed:
20
7
2024
entrez:
20
7
2024
Statut:
aheadofprint
Résumé
Gastric mucins serve as a protective barrier on the stomach's surface, protecting from external stimuli including gastric acid and gut microbiota. Their composition typically changes in response to the metaplastic sequence triggered by Helicobacter pylori infection. This alteration in gastric mucins is also observed in cases of gastric cancer, although the precise connection between mucin expressions and gastric carcinogenesis remains uncertain. This review first introduces the relationship between mucin expressions and gastric metaplasia or cancer observed in humans and mice. Additionally, we discuss potential pathogenic mechanisms of how aberrant mucins and their glycans affect gastric carcinogenesis. Finally, we summarize challenges to target tumor-specific glycans by utilizing lectin-drug conjugates that can bind to specific glycans. Understanding the correlation and mechanism between these mucin expressions and gastric carcinogenesis could pave the way for new strategies in gastric cancer treatment.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Society for the Promotion of Science
ID : 23H02744
Organisme : Japan Society for the Promotion of Science
ID : 24K18531
Organisme : Kato Memorial Bioscience Foundation
Organisme : P-CREATE/PROMOTE from AMED
Organisme : Advanced Research and Development Programs for Medical Innovation (PRIME)
Informations de copyright
© 2024 The Author(s). Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
McGuckin MA, Lindén SK, Sutton P, Florin TH. Mucin dynamics and enteric pathogens. Nat Rev Microbiol. 2011;9(4):265‐278.
Hansson GC. Mucins and the microbiome. Annu Rev Biochem. 2020;89:769‐793.
Niwa T, Ikehara Y, Nakanishi H, et al. Mixed gastric‐ and intestinal‐type metaplasia is formed by cells with dual intestinal and gastric differentiation. J Histochem Cytochem. 2005;53(1):75‐85.
Kobayashi T, Omori Y, Ono Y, et al. Pathways for the development of multiple epithelial types of intraductal papillary mucinous neoplasm of the pancreas. J Gastroenterol. 2021;56(6):581‐592.
Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15(9):540‐555.
Hayakawa Y, Nakagawa H, Rustgi AK, Que J, Wang TC. Stem cells and origins of cancer in the upper gastrointestinal tract. Cell Stem Cell. 2021;28(8):1343‐1361.
Oya Y, Hayakawa Y, Koike K. Tumor microenvironment in gastric cancers. Cancer Sci. 2020;111(8):2696‐2707.
Hata M, Hayakawa Y, Koike K. Gastric stem cell and cellular origin of cancer. Biomedicine. 2018;6(4):100.
Kinoshita H, Hayakawa Y, Koike K. Metaplasia in the stomach‐precursor of gastric cancer? Int J Mol Sci. 2017;18(10):2063.
Hayakawa Y, Sakitani K, Konishi M, et al. Nerve growth factor promotes gastric tumorigenesis through aberrant cholinergic signaling. Cancer Cell. 2017;31(1):21‐34.
Hayakawa Y, Fox JG, Gonda T, Worthley DL, Muthupalani S, Wang TC. Mouse models of gastric cancer. Cancers (Basel). 2013;5(1):92‐130.
Johansson ME, Sjövall H, Hansson GC. The gastrointestinal mucus system in health and disease. Nat Rev Gastroenterol Hepatol. 2013;10(6):352‐361.
Atuma C, Strugula V, Allen A, Holm L. The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am J Physiol. 2001;280:G922‐G929.
Phillipson M, Atuma C, Henriksnas J, Holm L. The importance of mucus layers and bicarbonate transport in preservation of gastric juxtamucosal pH. Am J Physiol. 2002;282:G211‐G219.
Bhaskar KR, Garik P, Turner BS, et al. Viscous fingering of HCl through gastric mucin. Nature. 1992;360:458‐461.
Niikura R, Hayakawa Y, Nagata N, et al. Non‐Helicobacter pylori gastric microbiome modulates prooncogenic responses and is associated with gastric cancer risk. Gastro Hep Advances. 2023;2:684‐700.
Boccellato F, Woelffling S, Imai‐Matsushima A, et al. Polarised epithelial monolayers of the gastric mucosa reveal insights into mucosal homeostasis and defence against infection. Gut. 2019;68(3):400‐413.
Van den Brink GR, Tytgat KM, Van der Hulst RW, et al. H pylori colocalises with MUC5AC in the human stomach. Gut. 2000;46(5):601‐607.
Kawakubo M, Ito Y, Okimura Y, et al. Natural antibiotic function of a human gastric mucin against Helicobacter pylori infection. Science. 2004;305(5686):1003‐1006.
Kobayashi M, Lee H, Nakayama J, Fukuda M. Roles of gastric mucin‐type O‐glycans in the pathogenesis of Helicobacter pylori infection. Glycobiology. 2009;19(5):453‐461.
Arai J, Niikura R, Hayakawa Y, et al. Use of antibiotics and probiotics reduces the risk of metachronous gastric cancer after endoscopic resection. Biology (Basel). 2021;10(6):455.
Correa P, Piazuelo MB. The gastric precancerous cascade. J Dig Dis. 2012;13(1):2‐9.
Babu SD, Jayanthi V, Devaraj N, Reis CA, Devaraj H. Expression profile of mucins (MUC2, MUC5AC and MUC6) in Helicobacter pylori infected pre‐neoplastic and neoplastic human gastric epithelium. Mol Cancer. 2006;5:10. doi:10.1186/1476-4598-5-10
Arai J, Aoki T, Sato M, et al. Machine learning‐based personalized prediction of gastric cancer incidence using the endoscopic and histologic findings at the initial endoscopy. Gastrointest Endosc. 2022;95(5):864‐872.
Arai J, Niikura R, Hayakawa Y, et al. OLGIM staging and proton pump inhibitor use predict the risk of gastric cancer. Gut. 2022;71(5):1043‐1044.
Arai J, Aoki T, Hayakawa Y, et al. Letter: Predictive model for gastric cancer after eradication of Helicobacter pylori‐a survival analysis using a deep learning algorithm. Aliment Pharmacol Ther. 2021;54(4):528‐529.
Arai J, Niikura R, Hayakawa Y, Hirata Y, Ushiku T, Fujishiro M. Autoimmune gastritis may be less susceptible to cancer development than Helicobacter pylori‐related gastritis based on histological analysis. Gut. 2023;73:1037‐1038.
Shichijo S, Hirata Y, Niikura R, et al. Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication. Gastrointest Endosc. 2016;84(4):618‐624.
Tsuboi M, Niikura R, Hayakawa Y, Hirata Y, Ushiku T, Koike K. Distinct features of autoimmune gastritis in patients with open‐type chronic gastritis in Japan. Biomedicine. 2020;8(10):419.
Niikura R, Hayakawa Y, Hirata Y, et al. The reduction in gastric atrophy after Helicobacter pylori eradication is reduced by treatment with inhibitors of gastric acid secretion. Int J Mol Sci. 2019;20(8):1913.
Hayakawa Y, Sethi N, Sepulveda AR, Bass AJ, Wang TC. Oesophageal adenocarcinoma and gastric cancer: should we mind the gap? Nat Rev Cancer. 2016;16(5):305‐318.
Fujii Y, Yoshihashi K, Suzuki H, et al. CDX1 confers intestinal phenotype on gastric epithelial cells via induction of stemness‐associated reprogramming factors SALL4 and KLF5. Proc Natl Acad Sci USA. 2012;109(50):20584‐20589.
Nienhüser H, Kim W, Malagola E, et al. Mist1+ gastric isthmus stem cells are regulated by Wnt5a and expand in response to injury and inflammation in mice. Gut. 2021;70(4):654‐665.
Hata M, Kinoshita H, Hayakawa Y, et al. GPR30‐expressing gastric chief cells do not dedifferentiate but are eliminated via PDK‐dependent cell competition during development of metaplasia. Gastroenterology. 2020;158(6):1650‐1666.
Kinoshita H, Hayakawa Y, Niu Z, et al. Mature gastric chief cells are not required for the development of metaplasia. Am J Physiol Gastrointest Liver Physiol. 2018;314(5):G583‐G596.
Hayakawa Y, Fox JG, Wang TC. Isthmus stem cells are the origins of metaplasia in the gastric corpus. Cell Mol Gastroenterol Hepatol. 2017;4(1):89‐94.
Hayakawa Y, Fox JG, Wang TC. The origins of gastric cancer from gastric stem cells: lessons from mouse models. Cell Mol Gastroenterol Hepatol. 2017;3(3):331‐338.
Serizawa T, Hirata Y, Hayakawa Y, et al. Gastric metaplasia induced by Helicobacter pylori is associated with enhanced SOX9 expression via Interleukin‐1 signaling. Infect Immun. 2015;84(2):562‐572.
Hayakawa Y, Ariyama H, Stancikova J, et al. Mist1 expressing gastric stem cells maintain the Normal and neoplastic gastric epithelium and are supported by a perivascular stem cell niche. Cancer Cell. 2015;28(6):800‐814.
Farrell JJ, Taupin D, Koh TJ, et al. TFF2/SP‐deficient mice show decreased gastric proliferation, increased acid secretion, and increased susceptibility to NSAID injury. J Clin Invest. 2002;109(2):193‐204.
Wang XT, Kong FB, Mai W, Li L, Pang LM. MUC1 immunohistochemical expression as a prognostic factor in gastric cancer: meta‐analysis. Dis Markers. 2016;2016:9421571.
Wang RQ, Fang DC. Alterations of MUC1 and MUC3 expression in gastric carcinoma: relevance to patient clinicopathological features. J Clin Pathol. 2003;56(5):378‐384.
Tamura Y, Higashi M, Kitamoto S, et al. MUC4 and MUC1 expression in adenocarcinoma of the stomach correlates with vessel invasion and lymph node metastasis: an immunohistochemical study of early gastric cancer. PLoS ONE. 2012;7(11):e49251.
Dai W, Liu J, Liu B, Li Q, Sang Q, Li YY. Systematical analysis of the cancer genome atlas database reveals EMCN/MUC15 combination as a prognostic signature for gastric cancer. Front Mol Biosci. 2020;7:19.
Pinto‐de‐Sousa J, Reis CA, David L, Pimenta A, Cardoso‐de‐Oliveira M. MUC5B expression in gastric carcinoma: relationship with clinico‐pathological parameters and with expression of mucins MUC1, MUC2, MUC5AC and MUC6. Virchows Arch. 2004;444(3):224‐230.
Shimamura T, Ito H, Shibahara J, et al. Overexpression of MUC13 is associated with intestinal‐type gastric cancer. Cancer Sci. 2005;96(5):265‐273.
de Bolos C, Real FX, Lopez‐Ferrer A. Regulation of mucin and glycoconjugate expression: from normal epithelium to gastric tumors. Front Biosci. 2001;6:D1256‐D1263.
Zhang F, Li X, Chen H, et al. Mutation of MUC16 is associated with tumor mutational burden and lymph node metastasis in patients with gastric cancer. Front Med (Lausanne). 2022;9:836892.
Yang B, Wu A, Hu Y, et al. Mucin 17 inhibits the progression of human gastric cancer by limiting inflammatory responses through a MYH9‐p53‐RhoA regulatory feedback loop. J Exp Clin Cancer Res. 2019;38(1):283.
Tatematsu M, Tsukamoto T, Inada K. Stem cells and gastric cancer: role of gastric and intestinal mixed intestinal metaplasia. Cancer Sci. 2003;94:135‐141.
Endoh Y, Tamura G, Ajioka Y, Watanabe H, Motoyama T. Frequent hypermethylation of the hMLH1 gene promoter in differentiated‐type tumors of the stomach with the gastric foveolar phenotype. Am J Pathol. 2000;157:717‐722.
Yokozaki H, Shitara Y, Fujimoto J, Hiyama T, Yasui W, Tahara E. Alterations of p73 preferentially occur in gastric adenocarcinomas with foveolar epithelial phenotype. Int J Cancer. 1999;83:192‐196.
Endoh Y, Tamura G, Watanabe H, Ajioka Y, Motoyama T. The common 18‐base pair deletion at codons 418‐423 of the E‐cadherin gene in differentiated‐type adenocarcinomas and intramucosal precancerous lesions of the stomach with the features of gastric foveolar epithelium. J Pathol. 1999;189:201‐206.
Endoh Y, Sakata K, Tamura G, et al. Cellular phenotypes of differentiated‐type adenocarcinomas and precancerous lesions of the stomach are dependent on the genetic pathways. J Pathol. 1999;191:257‐263.
Motoshita J, Oue N, Nakayama H, et al. DNA methylation profiles of differentiated‐type gastric carcinomas with distinct mucin phenotypes. Cancer Sci. 2005;96:474‐479.
Benahmed F, Gross I, Gaunt SJ, et al. Multiple regulatory regions control the complex expression pattern of the mouse Cdx2 homeobox gene. Gastroenterology. 2008;135:1238‐1247.
Tajima Y, Shimoda T, Nakanishi Y, et al. Association of gastric and intestinal phenotypic marker expression of gastric carcinomas with tumor thymidylate synthase expression and response to postoperative chemotherapy with 5‐fluorouracil. J Cancer Res Clin Oncol. 2003;129:683‐690.
Arai J, Niikura R, Hayakawa Y, et al. Clinicopathological features of gastric cancer with autoimmune gastritis. Biomedicine. 2022;10(4):884.
Mitani Y, Oue N, Matsumura S, et al. Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5‐fluorouracil‐based chemotherapy. Oncogene. 2007;26:4383‐4393.
Wang K, Yuen ST, Xu J, et al. Whole‐genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. 2014;46(6):573‐582.
Cristescu R, Lee J, Nebozhyn M, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21(5):449‐456.
Totoki Y, Saito‐Adachi M, Shiraishi Y, et al. Multiancestry genomic and transcriptomic analysis of gastric cancer. Nat Genet. 2023;55(4):581‐594.
Garcia E, Carvalho F, Amorim A, David L. MUC6 gene polymorphism in healthy individuals and in gastric cancer patients from northern Portugal. Cancer Epidemiol Biomarkers Prev. 1997;6(12):1071‐1074.
Kwon JA, Lee SY, Ahn EK, et al. Short rare MUC6 minisatellites‐5 alleles influence susceptibility to gastric carcinoma by regulating gene. Hum Mutat. 2010;31(8):942‐949.
Zheng H, Takahashi H, Nakajima T, et al. MUC6 down‐regulation correlates with gastric carcinoma progression and a poor prognosis: an immunohistochemical study with tissue microarrays. J Cancer Res Clin Oncol. 2006;132(12):817‐823.
Arai J, Hayakawa Y, Tateno H, et al. Impaired glycosylation of gastric mucins drives gastric tumorigenesis and serves as a novel therapeutic target. Gastroenterology. 2024. doi:10.1053/j.gastro.2024.03.037
Karasawa F, Shiota A, Goso Y, et al. Essential role of gastric gland mucin in preventing gastric cancer in mice. J Clin Invest. 2012;122:923‐934.
Liu F, Fu J, Bergstrom K, et al. Core 1‐derived mucin‐type O‐glycosylation protects against spontaneous gastritis and gastric cancer. J Exp Med. 2020;217:e20182325.
Fujii C, Harumiya S, Sato Y, Kawakubo M, Matoba H, Nakayama J. α1,4‐linked N‐acetylglucosamine suppresses gastric cancer development by inhibiting Mucin‐1‐mediated signaling. Cancer Sci. 2022;113(11):3852‐3863.
Mereiter S, Martins ÁM, Gomes C, et al. O‐glycan truncation enhances cancer‐related functions of CD44 in gastric cancer. FEBS Lett. 2019;593(13):1675‐1689.
Freitas D, Campos D, Gomes J, et al. O‐glycans truncation modulates gastric cancer cell signaling and transcription leading to a more aggressive phenotype. EBioMedicine. 2019;40:349‐362.
Muthupalani S, Ge Z, Joy J, et al. Muc5ac null mice are predisposed to spontaneous gastric antro‐pyloric hyperplasia and adenomas coupled with attenuated H. pylori‐induced corpus mucous metaplasia. Lab Invest. 2019;99(12):1887‐1905.
Leon F, Seshacharyulu P, Nimmakayala RK, et al. Reduction in O‐glycome induces differentially glycosylated CD44 to promote stemness and metastasis in pancreatic cancer. Oncogene. 2022;41(1):57‐71.
Lin NY, Lee JJ, Chen ST, et al. Truncation of GalNAc‐type O‐glycans suppresses CD44‐mediated Osteoclastogenesis and bone metastasis in breast cancer. Mol Cancer Res. 2023;21(7):664‐674.
Yuki A, Fujii C, Yamanoi K, et al. Glycosylation of MUC6 by α1,4‐linked N‐acetylglucosamine enhances suppression of pancreatic cancer malignancy. Cancer Sci. 2022;113(2):576‐586.
Velcich A, Yang W, Heyer J, et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science. 2002;295(5560):1726‐1729.
Yang Y, Akashi Y, Shimomura O, et al. Glycan expression profile of signet ring cell gastric cancer cells and potential applicability of rBC2LCN‐targeted lectin drug conjugate therapy. Gastric Cancer. 2022;25(5):896‐905.
Furuta T, Oda T, Kiyoi K, et al. Carcinoembryonic antigen as a specific glycoprotein ligand of rBC2LCN lectin on pancreatic ductal adenocarcinoma cells. Cancer Sci. 2021;112:3722‐3731.
Shimomura O, Oda T, Tateno H, et al. A novel therapeutic strategy for pancreatic cancer: targeting cell surface glycan using rBC2LC‐N lectin‐drug conjugate (LDC). Mol Cancer Ther. 2018;17:183‐195.